Author

Emmanuelle Magherini

Observed names: E Magherini, E. Magherini

Observed institutions: University of North Carolina at Chapel Hill, BC Cancer Agency, Cliniques Universitaires Saint-Luc, University of British Columbia, University of Alberta, Inserm, Institut Jules Bordet, Institut Gustave Roussy, Sanofi (France), Centre Hospitalier Universitaire de Lille, Ege University, Centre Hospitalier Universitaire de Besançon, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Saint-Antoine, Centre Léon Bérard, Centre Eugène Marquis, Centre Hospitalier de Beauvais, Hôpital Clinique Claude-Bernard, Royal Marsden Hospital, Pitié-Salpêtrière Hospital, Centre François Baclesse, Hôpitaux Universitaires Henri-Mondor, Hôpital Ambroise-Paré, Hôpital Purpan, Vancouver Coastal Health Research Institute, Institut Paoli-Calmettes, Centre Antoine Lacassagne, Institut Jean Godinot, Hôpital Paul-Brousse, Hôpital Tenon, UNC Lineberger Comprehensive Cancer Center, Cross Cancer Institute

OpenAlex ID: A5083604333

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

2009 · Judith Hugh, John Hanson, et al. · Journal of Clinical Oncology · 538

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

2013 · Ian F Tannock, Karim Fizazi, et al. · The Lancet Oncology · 299

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

2005 · Thierry Conroy, Bernard Paillot, et al. · Journal of Clinical Oncology · 240

Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand

2005 · Florian Scotté, Jean-Marc Tourani, et al. · Journal of Clinical Oncology · 197

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

2004 · E. Mitry, J.-Y. Douillard, et al. · Annals of Oncology · 127

PDF

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

2011 · C. Villanueva, A. Awada, et al. · European Journal of Cancer · 65

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level

2006 · Valérie Boige, Julien Taïeb, et al. · European Journal of Cancer · 65

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

2004 · F. Quenet, B. Nordlinger, et al. · Journal of Clinical Oncology · 45

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

2017 · Paul Ruff, Eric Van Cutsem, et al. · Journal of Geriatric Oncology · 36

Aflibercept Plus Folfiri in Asian Patients with Pretreated Metastatic Colorectal Cancer: A Randomized Phase III Study

2018 · Jin Li, Ruihua Xu, et al. · Future Oncology · 30

PDF

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).

2013 · Ian Tannock, Karim Fizazi, et al. · Journal of Clinical Oncology · 21

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

2004 · V�ronique Di�ras, Jean Paul Guastalla, et al. · Cancer Chemotherapy and Pharmacology · 16

Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer –A pooled analysis of 254 patients included in 2 randomised trials

2004 · E. Mitry, C. Tournigand, et al. · Journal of Clinical Oncology · 14

A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel

2013 · Pierre Maison-Blanche, Jan B. Vermorken, et al. · Journal of Cardiovascular Pharmacology · 5

Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC).

2013 · Ian Tannock, Karim Fizazi, et al. · Journal of Clinical Oncology · 4

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results

2009 · T. Besse-Hammer, C. Villanueva, et al. · Journal of Clinical Oncology · 4

Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study

2004 · F. Scotte, J. M. Tourani, et al. · Journal of Clinical Oncology · 4

Acute myelogenous leukemia with T-cell features.

1992 · V Ribrag, C Bayle, et al. · PubMed · 4

Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC)

2004 · V. Boige, J. Taieb, et al. · Journal of Clinical Oncology · 3

5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial

2004 · P. Piedbois, T. André, et al. · Journal of Clinical Oncology · 3

Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC)

2004 · G. Pascal, B. Nordlinger, et al. · Journal of Clinical Oncology · 2

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

2009 · C. Villanueva, A. Awada, et al. · European Journal of Cancer Supplements · 1

Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study

2004 · S. Nguyen, M. Flesch, et al. · Journal of Clinical Oncology · 1

Evidence for enhanced toxicity to CPT-11 in patients with Gilbert's syndrome: Two case reprots

1997 · E. Wasserman, A. Myara, et al. · European Journal of Cancer · 1

A retrospective comparison of the ability of lesion volumes and longest diameters to predict clinical outcome in metastatic colorectal cancer.

2015 · David Raunig, Ninad Mantri, et al. · Journal of Clinical Oncology

Works count: 29

Citation count: 1,725

H-index: 13

I10-index: 13